Related Experiment Video
Updated: Jun 22, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Fluvastatin in combination with other lipid-lowering agents
1Cardiovascular Clinical Research, Sandoz Research Institute, New Jersey, USA.
British Journal of Clinical Practice. Supplement
|June 6, 2009
Summary
Fluvastatin combined with bezafibrate or cholestyramine effectively lowers LDL cholesterol. Combination therapy with fluvastatin and niacin also showed significant lipid-lowering effects without safety concerns.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Biochemistry
Background:
- HMGCoA reductase inhibitors, like fluvastatin, are crucial for managing hypercholesterolaemia.
- Combination therapy is often necessary for patients with severe or mixed dyslipidaemia.
- Assessing the safety and efficacy of fluvastatin in combination with other lipid-modifying agents is important.
Purpose of the Study:
- To evaluate the efficacy and safety of fluvastatin in combination with bezafibrate, cholestyramine, and niacin.
- To compare the lipid-lowering effects of fluvastatin combinations versus monotherapy.
- To investigate potential adverse effects, such as myotoxicity, with fluvastatin combination therapies.
Main Methods:
- Double-blind trial of fluvastatin with bezafibrate or cholestyramine in familial hypercholesterolaemia.
- Dose-ranging study of fluvastatin with cholestyramine.
- Open-label study of fluvastatin followed by niacin administration.
- Monitoring of lipid profiles and safety markers (creatine kinase, liver transaminases).
Main Results:
- Fluvastatin-bezafibrate combination showed greater HDL-C increase and triglyceride reduction than fluvastatin-cholestyramine.
- Fluvastatin-cholestyramine combinations achieved significant LDL-C reductions, dose-dependently.
- Fluvastatin-niacin combination resulted in a 43.7% LDL-C reduction, superior to niacin monotherapy (26.5%).
- No significant elevations in creatine kinase or liver transaminases, and no myopathy reported across combinations.
Conclusions:
- Combination therapy with fluvastatin and bezafibrate, cholestyramine, or niacin demonstrates significant lipid-lowering efficacy.
- These combinations appear well-tolerated, with a favorable safety profile regarding myotoxicity and liver enzyme elevation.
- Combination therapies offer a promising strategy for managing patients with hypercholesterolaemia and mixed dyslipidaemia.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...